About adial pharmaceuticals inc - ADIL
Adial Pharmaceuticals, Inc. engages in the development of therapeutics for the treatment or prevention of addiction and related disorders. It offers the AD04, a selective serotonin-3 antagonist. The company was founded by Bankole A. Johnson and William B. Stilley, III in November 2010 and is headquartered in Glen Allen, VA.
ADIL At a Glance
Adial Pharmaceuticals, Inc.
4870 Sadler Road
Glen Allen, Virginia 23060
| Phone | 1-434-487-8196 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -7,977,171.00 | |
| Sector | Health Technology | Employees | 6 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
ADIL Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 1.158 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.283 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | N/A |
ADIL Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,329,528.50 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
ADIL Liquidity
| Current Ratio | 4.425 |
| Quick Ratio | 4.425 |
| Cash Ratio | 4.21 |
ADIL Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -134.289 |
| Return on Equity | -170.734 |
| Return on Total Capital | -151.184 |
| Return on Invested Capital | -170.734 |
ADIL Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | N/A |
| Total Debt to Total Assets | N/A |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |